What's The BUZZ?

Market News, Products, Services, and Trends

Dr. Reddy's Laboratories Ltd.

Dr. Reddy’s Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

VISIT WEBSITE
Dr. Reddy’s Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

2020-06-16_1043.png



TODAY'S POSTS
SUBSCRIBE
Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. News & Announcements

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

PROFILE
WEBSITE
10-rxinsider-staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

PROFILE
LINKEDIN
WEBSITE

This post is related to:

TODAY'S POSTS

Connect with RXinsider

Stay informed on pharmacy supply chain news, market trends, and product releases by subscribing to RXinsider’s emails, newsletters, and publications. If building awareness with pharmacy management is part of your marketing strategy, consider advertising with RXinsider.

Subscribe
Advertise

RXinsider
1300 Division Road, Suite 103
West Warwick, RI 02893

The BUZZ / News

Publications

Marketplace

Multimedia Content

Market Intelligence

Career Center

Subscribe

Company

Subscribe
© 2025 RXinsider | All Rights Reserved.

SUBSCRIBE

Please enable JavaScript in your browser to complete this form.
Name
Subscription Choices
Checkboxes

Request information from Dr. Reddy’s Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

Please enable JavaScript in your browser to complete this form.
Name
Address
Subscribe